Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.

Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ.

J Clin Invest. 2019 Feb 4. pii: 99296. doi: 10.1172/JCI99296. [Epub ahead of print]

2.

C3 glomerulopathy - understanding a rare complement-driven renal disease.

Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM.

Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2. Review.

PMID:
30692664
3.

Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis.

Wilson HR, Medjeral-Thomas NR, Gilmore AC, Trivedi P, Seyb K, Farzaneh-Far R, Gunnarsson I, Zickert A, Cairns TD, Lightstone L, Cook HT, Pickering MC.

Kidney Int. 2019 Mar;95(3):655-665. doi: 10.1016/j.kint.2018.09.027. Epub 2019 Jan 14.

PMID:
30655025
4.

Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy.

Zhu L, Guo WY, Shi SF, Liu LJ, Lv JC, Medjeral-Thomas NR, Lomax-Browne HJ, Pickering MC, Zhang H.

Kidney Int. 2018 Jul;94(1):150-158. doi: 10.1016/j.kint.2018.02.023. Epub 2018 May 11.

PMID:
29759419
5.

Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectin-Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H-Related Protein-5 (FHR5) Deposition.

Medjeral-Thomas NR, Troldborg A, Constantinou N, Lomax-Browne HJ, Hansen AG, Willicombe M, Pusey CD, Cook HT, Thiel S, Pickering MC.

Kidney Int Rep. 2017 Nov 29;3(2):426-438. doi: 10.1016/j.ekir.2017.11.015. eCollection 2018 Mar.

6.

Distribution of exogenous complement factor H in mice in vivo.

Koskinen AR, Cheng ZZ, Pickering MC, Kairemo K, Meri T, Cook HT, Meri S, Jokiranta TS.

Scand J Immunol. 2018 Jul;88(1):e12671. doi: 10.1111/sji.12671. Epub 2018 May 23.

PMID:
29706017
7.

An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.

Yang Y, Denton H, Davies OR, Smith-Jackson K, Kerr H, Herbert AP, Barlow PN, Pickering MC, Marchbank KJ.

J Am Soc Nephrol. 2018 Jun;29(6):1649-1661. doi: 10.1681/ASN.2017091006. Epub 2018 Mar 27.

PMID:
29588430
8.

Extracellular DNA and autoimmune diseases.

Lou H, Pickering MC.

Cell Mol Immunol. 2018 Aug;15(8):746-755. doi: 10.1038/cmi.2017.136. Epub 2018 Mar 19. Review.

PMID:
29553134
9.

Autoimmune necrotising myopathy and HMGCR antibodies.

Karunaratne K, Amiras D, Pickering MC, Hofer M, Viegas S.

Pract Neurol. 2018 Apr;18(2):151-155. doi: 10.1136/practneurol-2017-001848. Epub 2018 Feb 8.

PMID:
29439058
10.

A triglyceride-rich lipoprotein environment exacerbates renal injury in the accelerated nephrotoxic nephritis model.

Saja MF, Cook HT, Ruseva MM, Szajna M, Pickering MC, Woollard KJ, Botto M.

Clin Exp Immunol. 2018 Jun;192(3):337-347. doi: 10.1111/cei.13111. Epub 2018 Mar 9.

11.

Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM.

Goetz L, Laskowski J, Renner B, Pickering MC, Kulik L, Klawitter J, Stites E, Christians U, van der Vlag J, Ravichandran K, Holers VM, Thurman JM.

Eur J Immunol. 2018 May;48(5):791-802. doi: 10.1002/eji.201747240. Epub 2018 Feb 22.

PMID:
29389016
12.

Clusters Not Classifications: Making Sense of Complement-Mediated Kidney Injury.

Cook HT, Pickering MC.

J Am Soc Nephrol. 2018 Jan;29(1):9-12. doi: 10.1681/ASN.2017111183. Epub 2017 Dec 11. No abstract available.

13.

Complement Regulatory Protein Factor H Is a Soluble Prion Receptor That Potentiates Peripheral Prion Pathogenesis.

Kane SJ, Farley TK, Gordon EO, Estep J, Bender HR, Moreno JA, Bartz J, Telling GC, Pickering MC, Zabel MD.

J Immunol. 2017 Dec 1;199(11):3821-3827. doi: 10.4049/jimmunol.1701100. Epub 2017 Oct 25.

14.

The complement system as a potential therapeutic target in rheumatic disease.

Trouw LA, Pickering MC, Blom AM.

Nat Rev Rheumatol. 2017 Sep;13(9):538-547. doi: 10.1038/nrrheum.2017.125. Epub 2017 Aug 10. Review.

PMID:
28794515
15.

Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy.

Medjeral-Thomas NR, Lomax-Browne HJ, Beckwith H, Willicombe M, McLean AG, Brookes P, Pusey CD, Falchi M, Cook HT, Pickering MC.

Kidney Int. 2017 Oct;92(4):942-952. doi: 10.1016/j.kint.2017.03.043. Epub 2017 Jun 30.

16.

Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients-a potential biomarker of disease activity.

Stratigou V, Doyle AF, Carlucci F, Stephens L, Foschi V, Castelli M, McKenna N, Cook HT, Lightstone L, Cairns TD, Pickering MC, Botto M.

Rheumatology (Oxford). 2017 Jul 1;56(7):1206-1216. doi: 10.1093/rheumatology/kex078.

17.

Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation.

Calippe B, Augustin S, Beguier F, Charles-Messance H, Poupel L, Conart JB, Hu SJ, Lavalette S, Fauvet A, Rayes J, Levy O, Raoul W, Fitting C, Denèfle T, Pickering MC, Harris C, Jorieux S, Sullivan PM, Sahel JA, Karoyan P, Sapieha P, Guillonneau X, Gautier EL, Sennlaub F.

Immunity. 2017 Feb 21;46(2):261-272. doi: 10.1016/j.immuni.2017.01.006.

18.

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants.

Kidney Int. 2017 Mar;91(3):539-551. doi: 10.1016/j.kint.2016.10.005. Epub 2016 Dec 16.

19.

The complement factor H-related proteins.

Medjeral-Thomas N, Pickering MC.

Immunol Rev. 2016 Nov;274(1):191-201. doi: 10.1111/imr.12477. Review.

PMID:
27782332
20.

IgA1 Glycosylation Is Heritable in Healthy Twins.

Lomax-Browne HJ, Visconti A, Pusey CD, Cook HT, Spector TD, Pickering MC, Falchi M.

J Am Soc Nephrol. 2017 Jan;28(1):64-68. doi: 10.1681/ASN.2016020184. Epub 2016 Jun 16.

21.

Abnormally High Content of Free Glucosamine Residues Identified in a Preparation of Commercially Available Porcine Intestinal Heparan Sulfate.

Mulloy B, Wu N, Gyapon-Quast F, Lin L, Zhang F, Pickering MC, Linhardt RJ, Feizi T, Chai W.

Anal Chem. 2016 Jul 5;88(13):6648-52. doi: 10.1021/acs.analchem.6b01662. Epub 2016 Jun 15.

22.

Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.

Laskowski J, Renner B, Le Quintrec M, Panzer S, Hannan JP, Ljubanovic D, Ruseva MM, Borza DB, Antonioli AH, Pickering MC, Holers VM, Thurman JM.

Kidney Int. 2016 Jul;90(1):109-22. doi: 10.1016/j.kint.2016.02.036. Epub 2016 May 7.

23.

Increased Autoreactivity of the Complement-Activating Molecule Mannan-Binding Lectin in a Type 1 Diabetes Model.

Østergaard JA, Ruseva MM, Malik TH, Hoffmann-Petersen IT, Pickering MC, Thiel S, Hansen TK.

J Diabetes Res. 2016;2016:1825738. doi: 10.1155/2016/1825738. Epub 2016 Feb 10.

24.

Trapped without a diagnosis: Tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

Kirresh A, Everitt A, Kon OM, DasGupta R, Pickering MC, Lachmann HJ.

Pract Neurol. 2016 Aug;16(4):304-7. doi: 10.1136/practneurol-2015-001342. Epub 2016 Mar 10.

PMID:
26965498
25.

Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy.

Barbour TD, Ling GS, Ruseva MM, Fossati-Jimack L, Cook HT, Botto M, Pickering MC.

Kidney Int. 2016 Apr;89(4):823-32. doi: 10.1016/j.kint.2015.11.024. Epub 2016 Feb 3.

26.

Complement Factor H Serum Levels Determine Resistance to Pneumococcal Invasive Disease.

van der Maten E, Westra D, van Selm S, Langereis JD, Bootsma HJ, van Opzeeland FJ, de Groot R, Ruseva MM, Pickering MC, van den Heuvel LP, van de Kar NC, de Jonge MI, van der Flier M.

J Infect Dis. 2016 Jun 1;213(11):1820-7. doi: 10.1093/infdis/jiw029. Epub 2016 Jan 21.

27.

Annexin A2 Enhances Complement Activation by Inhibiting Factor H.

Renner B, Tong HH, Laskowski J, Jonscher K, Goetz L, Woolaver R, Hannan J, Li YX, Hourcade D, Pickering MC, Holers VM, Thurman JM.

J Immunol. 2016 Feb 1;196(3):1355-65. doi: 10.4049/jimmunol.1500793. Epub 2016 Jan 4.

28.

Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.

Vernon KA, Ruseva MM, Cook HT, Botto M, Malik TH, Pickering MC.

J Am Soc Nephrol. 2016 May;27(5):1334-42. doi: 10.1681/ASN.2015030295. Epub 2015 Sep 15.

29.

Triglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1(low) Monocytes.

Saja MF, Baudino L, Jackson WD, Cook HT, Malik TH, Fossati-Jimack L, Ruseva M, Pickering MC, Woollard KJ, Botto M.

Cell Rep. 2015 Sep 22;12(11):1802-15. doi: 10.1016/j.celrep.2015.08.020. Epub 2015 Sep 3.

30.

Eculizumab as rescue therapy in severe resistant lupus nephritis.

Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, Terence Cook H, Cairns TD.

Rheumatology (Oxford). 2015 Dec;54(12):2286-8. doi: 10.1093/rheumatology/kev307. Epub 2015 Aug 27. No abstract available.

31.

An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.

Nichols EM, Barbour TD, Pappworth IY, Wong EK, Palmer JM, Sheerin NS, Pickering MC, Marchbank KJ.

Kidney Int. 2015 Dec;88(6):1314-1322. doi: 10.1038/ki.2015.233. Epub 2015 Jul 29.

32.

Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.

Ruseva MM, Peng T, Lasaro MA, Bouchard K, Liu-Chen S, Sun F, Yu ZX, Marozsan A, Wang Y, Pickering MC.

J Am Soc Nephrol. 2016 Feb;27(2):405-16. doi: 10.1681/ASN.2014121195. Epub 2015 Jun 5.

33.

IgM exacerbates glomerular disease progression in complement-induced glomerulopathy.

Panzer SE, Laskowski J, Renner B, Kulik L, Ljubanovic D, Huber KM, Zhong W, Pickering MC, Holers VM, Thurman JM.

Kidney Int. 2015 Sep;88(3):528-37. doi: 10.1038/ki.2015.120. Epub 2015 May 6.

34.

Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation.

Csincsi ÁI, Kopp A, Zöldi M, Bánlaki Z, Uzonyi B, Hebecker M, Caesar JJ, Pickering MC, Daigo K, Hamakubo T, Lea SM, Goicoechea de Jorge E, Józsi M.

J Immunol. 2015 May 15;194(10):4963-73. doi: 10.4049/jimmunol.1403121. Epub 2015 Apr 8.

35.

Competition between antagonistic complement factors for a single protein on N. meningitidis rules disease susceptibility.

Caesar JJ, Lavender H, Ward PN, Exley RM, Eaton J, Chittock E, Malik TH, Goiecoechea De Jorge E, Pickering MC, Tang CM, Lea SM.

Elife. 2014 Dec 23;3. doi: 10.7554/eLife.04008.

36.

Histopathology of MPGN and C3 glomerulopathies.

Cook HT, Pickering MC.

Nat Rev Nephrol. 2015 Jan;11(1):14-22. doi: 10.1038/nrneph.2014.217. Epub 2014 Dec 2. Review.

PMID:
25447133
37.

Update on C3 glomerulopathy.

Barbour TD, Ruseva MM, Pickering MC.

Nephrol Dial Transplant. 2016 May;31(5):717-25. doi: 10.1093/ndt/gfu317. Epub 2014 Oct 17. Review.

38.

C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.

Xiao X, Pickering MC, Smith RJ.

Semin Thromb Hemost. 2014 Jun;40(4):465-71. doi: 10.1055/s-0034-1376334. Epub 2014 May 5. Review.

PMID:
24799308
39.

Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates.

van der Veen S, Johnson S, Jongerius I, Malik T, Genovese A, Santini L, Staunton D, Ufret-Vincenty RL, Pickering MC, Lea SM, Tang CM.

Infect Immun. 2014 Mar;82(3):1157-63. doi: 10.1128/IAI.01183-13. Epub 2013 Dec 30.

40.

Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.

Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, Subias M, Pickering MC, Drouet C, Meri S, Arstila TP, Pekkarinen PT, Ma M, Cope A, Reinheckel T, Rodriguez de Cordoba S, Afzali B, Atkinson JP, Kemper C.

Immunity. 2013 Dec 12;39(6):1143-57. doi: 10.1016/j.immuni.2013.10.018. Epub 2013 Dec 5.

41.

C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo.

Ruseva MM, Takahashi M, Fujita T, Pickering MC.

Clin Exp Immunol. 2014 Apr;176(1):84-92. doi: 10.1111/cei.12244.

42.

C3 glomerulopathy: clinicopathologic features and predictors of outcome.

Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT.

Clin J Am Soc Nephrol. 2014 Jan;9(1):46-53. doi: 10.2215/CJN.04700513. Epub 2013 Oct 31.

43.

C3 glomerulopathy: consensus report.

Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT.

Kidney Int. 2013 Dec;84(6):1079-89. doi: 10.1038/ki.2013.377. Epub 2013 Oct 30.

44.

Dense deposit disease and C3 glomerulopathy.

Barbour TD, Pickering MC, Terence Cook H.

Semin Nephrol. 2013 Nov;33(6):493-507. doi: 10.1016/j.semnephrol.2013.08.002. Review.

45.

A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry.

Medjeral-Thomas N, Malik TH, Patel MP, Toth T, Cook HT, Tomson C, Pickering MC.

Kidney Int. 2014 Apr;85(4):933-7. doi: 10.1038/ki.2013.348. Epub 2013 Sep 25.

46.

Complement alternative pathway genetic variation and Dengue infection in the Thai population.

Kraivong R, Vasanawathana S, Limpitikul W, Malasit P, Tangthawornchaikul N, Botto M, Screaton GR, Mongkolsapaya J, Pickering MC.

Clin Exp Immunol. 2013 Nov;174(2):326-34. doi: 10.1111/cei.12184.

47.

Complement component C3 plays a critical role in protecting the aging retina in a murine model of age-related macular degeneration.

Hoh Kam J, Lenassi E, Malik TH, Pickering MC, Jeffery G.

Am J Pathol. 2013 Aug;183(2):480-92. doi: 10.1016/j.ajpath.2013.04.008. Epub 2013 Jun 6.

PMID:
23747511
48.

C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.

Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R, López Trascasa M, Pickering MC, Harris CL, Sánchez-Corral P, Llorca O, Rodríguez de Córdoba S.

J Clin Invest. 2013 Jun;123(6):2434-46.

49.

Detection of complement activation using monoclonal antibodies against C3d.

Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, Coughlin B, Woodell AS, Pickering MC, Rohrer B, Holers VM.

J Clin Invest. 2013 May;123(5):2218-30. doi: 10.1172/JCI65861. Epub 2013 Apr 24.

50.

Dimerization of complement factor H-related proteins modulates complement activation in vivo.

Goicoechea de Jorge E, Caesar JJ, Malik TH, Patel M, Colledge M, Johnson S, Hakobyan S, Morgan BP, Harris CL, Pickering MC, Lea SM.

Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4685-90. doi: 10.1073/pnas.1219260110. Epub 2013 Mar 4.

Supplemental Content

Loading ...
Support Center